Beijing, Beijing, China | Fund Name | Location |
| Aetna Ventures | Connecticut, Hartford, United States |
| Agentschap NL | - |
| Beijing Wojia Xinxi Zixun Zhongxin | Beijing, China, Haidian |
| Bitclick GmbH | - |
| Cali Group | California, Pasadena, United States |
| Double Peak Group | China, Hong Kong, Hong Kong Island |
| Framework Ventures | Canada, Ontario, Toronto |
| Insight Catastrophe Group | Jersey City, New Jersey, United States |
| Keller Capital | Austin, Texas, United States |
| KJS Ahluwalia Group | India, Keonjhar, Odisha |
| Lezhong Investment Management | China, Guangdong, Zhuhai |
| NBK Capital Partners | Dubai, United Arab Emirates |
| NSF Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR) | Arlington, United States, Virginia |
| Pierpoint Capital | New York, New York, United States |
| Skyviews Life Science | - |
| Spectra Investments | Brazil, São Paulo, Sao Paulo |
| True North Venture Partners | Chicago, Illinois, United States |
| WuXi PharmaTech | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
ReLive | $36M | 16 Jan 2023 | - | ||
Zenshine Pharma | $15M | 01 Dec 2020 | Nanjing, Jiangsu, China | ||
| 09 Apr 2020 | Haidian District, Beijing, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
ReLive | $36M | 16 Jan 2023 | - | ||
Zenshine Pharma | $15M | 01 Dec 2020 | Nanjing, Jiangsu, China | ||
| 09 Apr 2020 | Haidian District, Beijing, China |
